Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $91
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
BridgeBio to Participate in November and December Investor Conferences
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108
What Is BridgeBio Pharma (BBIO) Betting On With Three FDA Priority Launches?
TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100
BridgeBio (BBIO) Q3 2026 Earnings Call Transcript
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Raises Price Target to $88
BridgeBio Pharma, Inc. Q3 2026 Earnings Call Summary
What BridgeBio Pharma (BBIO) Said on Its Q3 Earnings Call
BridgeBio Pharma (NASDAQ:BBIO) Q3 Beat Masks Milestone-Reliant Revenue Ahead of Key PDUFA Catalysts
BridgeBio Pharma, Inc. (BBIO) Q3 2026 Earnings Call Transcript
BridgeBio Pharma (BBIO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BridgeBio Pharma: Q3 Earnings Snapshot
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
BridgeBio Pharma Q3 2026 Earnings Call Transcript
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
Morgan Stanley Maintains Overweight on BridgeBio Pharma, Lowers Price Target to $87
What BridgeBio Pharma Doubters Missed
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.